



OPAL BIOSCIENCES LIMITED

ABN 97 605 631 963

Level 4,

100 Albert Road,

South Melbourne, Victoria, 3205

Australia

Phone: +613 9692 7240

Web: www.opalbiosciences.com

Announcement

EOFY 2022 Information

Melbourne, 11 August 2022: Opal Biosciences Ltd (“Opal”) is pleased to provide the following update.

Opal’s strategic focus has been re-directed towards growing Australia’s vaccine and pharmaceutical manufacturing capability. The lack of onshore manufacturing capability and risks of reliance on imported medicines has become evident during the current pandemic.

Commercial opportunities are in discussion and last month Opal submitted an application for \$5m to the federal government’s Medical Research Future Fund’s mRNA Clinical Trial Enabling Infrastructure grant program. Additional applications are also in progress and discussions with state governments underway.

EOFY Share Price information

The EOFY 2022 share price of Opal Biosciences ordinary shares is \$0.075 (7.5 cents).

Shareholder Information at the share registry held by Vistra (previously Leydin Freyer).

Leydin Freyer has now become part of Vistra (<https://www.leydinfreyer.com.au/about/vistra-update/>). Vistra maintains Opal’s share registry. Shareholders can update their contact details and email addresses by contacting jphillips@opalbiosciences.com.

- ENDS -

Further information

Julie Phillips, Managing Director, Opal Biosciences Ltd

Phone +61 3 9692 7222

Email jphillips@opalbiosciences.com

Twitter @opalbiosciences